Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines

被引:10
作者
Thompson, Stephen R. [1 ,2 ,3 ]
Delaney, Geoff P. [1 ,3 ,4 ]
Jacob, Susannah [1 ,3 ]
Shafiq, Jesmin [1 ,3 ]
Wong, Karen [1 ,3 ]
Hanna, Timothy P. [5 ]
Gabriel, Gabriel S. [1 ,3 ]
Barton, Michael B. [1 ,3 ]
机构
[1] UNSW, Liverpool Hosp, Ingham Inst Appl Med Res, CCORE, Sydney, NSW, Australia
[2] Prince Wales Hosp, Dept Radiat Oncol, Sydney, NSW, Australia
[3] Univ New S Wales, Sydney, NSW, Australia
[4] Univ Western Sydney, Penrith, NSW 1797, Australia
[5] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada
关键词
Prostate cancer; Brachytherapy; Radiotherapy; Radical prostatectomy; Utilisation rate; Patterns of care; DEMAND; POPULATION; ENGLAND; NEED;
D O I
10.1016/j.radonc.2015.12.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: We aimed to construct an evidence-based model of optimal treatment utilisation for prostate cancer, incorporating all local treatment modalities: radical prostatectomy (RP), external beam radiotherapy (EBRT), and brachytherapy (BT); and then to compare this optimal model with actual practice. Materials and methods: Evidence-based guidelines were used to construct a prostate cancer treatment decision-tree. The proportion of patients who fulfilled treatment criteria was drawn from the epidemiological literature. These data were combined to calculate the overall proportion of patients that should optimally have RP, EBRT and/or BT at least once during the course of their disease. The model was peer reviewed and tested by sensitivity analyses and compared with actual practice. Results: Optimal utilisation rates, at some point during the disease course, were: RP, 24% (range 15-30%); EBRT, 58% (range 54-64%); BT, 9.6% (range 6.0-17.9%); and any RT, 60% (range 56-66%). Many patients had indications for more than one of these treatments, and at least one of these treatments was indicated in 76% of patients. The model was sensitive to patient preference estimates. Optimal rates were achievable in some health care jurisdictions. Conclusions: Modelling optimal utilisation of all local treatment options for a particular cancer is possible. These optimal prostate cancer treatment rates can be used as a planning and quality assurance tool, providing an evidence-based benchmark against which can be measured patterns of practice. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:118 / 121
页数:4
相关论文
共 50 条
  • [21] High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial
    Hoskin, Peter J.
    Motohashi, Kate
    Bownes, Peter
    Bryant, Linda
    Ostler, Peter
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 (02) : 114 - 120
  • [22] Salvage external beam radiotherapy for prostate cancer biochemical recurrence after radical prostatectomy
    Lopez-Lara Martin, Francisco
    Diezhandino Garcia, Patricia
    ARCHIVOS ESPANOLES DE UROLOGIA, 2012, 65 (01): : 131 - 144
  • [23] Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer
    Chun, Seok-Joo
    Kim, Jin Ho
    Ku, Ja Hyeon
    Kwak, Cheol
    Lee, Eun Sik
    Kim, Suzy
    RADIATION ONCOLOGY JOURNAL, 2021, 39 (03): : 231 - 238
  • [24] Second primary cancer after radiotherapy for prostate cancer - A SEER analysis of brachytherapy versus external beam radiotherapy
    Abdel-Wahab, May
    Reis, Isildinha M.
    Hamilton, Kara
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : 58 - 68
  • [25] Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
    Berdine L. Heesterman
    Katja K. H. Aben
    Igle Jan de Jong
    Floris J. Pos
    Olga L. van der Hel
    BMC Cancer, 23
  • [26] Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
    Heesterman, Berdine L.
    Aben, Katja K. H.
    de Jong, Igle Jan
    Pos, Floris J.
    van der Hel, Olga L.
    BMC CANCER, 2023, 23 (01)
  • [27] Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy
    Ni, Lisa
    Chen, Katherine
    Phuong, Christina
    Sabbagh, Ali R.
    Wong, Anthony C.
    Mohamad, Osama
    Hsu, I. -Chow
    BRACHYTHERAPY, 2023, 22 (03) : 304 - 309
  • [28] Optimal radiotherapy for prostate cancer: Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models
    King, CR
    DiPetrillo, TA
    Wazer, DE
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (01): : 165 - 172
  • [29] Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer
    Astrom, Lennart
    Grusell, Erik
    Sandin, Fredrik
    Turesson, Ingela
    Holmberg, Lars
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 (01) : 81 - 87
  • [30] Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer
    Ferrer, Montserrat
    Francisco Suarez, Jose
    Guedea, Ferran
    Fernandez, Pablo
    Macias, Victor
    Marino, Alfonso
    Hervas, Asuncion
    Herruzo, Ismael
    Jose Ortiz, Maria
    Villavicencio, Humberto
    Craven-Bratle, Jordi
    Garin, Olatz
    Aguilo, Ferran
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (02): : 421 - 432